This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound
![This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound](https://images.fastcompany.com/image/upload/w_1280,q_auto,f_auto,fl_lossy/wp-cms-2/2024/06/p-1-91137739-this-obesity-drug-startup-emerged-from-stealth-with-290-million-and-plans-to-take-on-wegovy-and-zepbound.jpg)
Metsera is taking a ‘Lego kit’ approach to finding a next-generation weight-loss treatment.
Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a portfolio of drug assets all focused on what may be the most lucrative pharmaceutical opportunity ever: obesity.